Teva Pharmaceutical Industries ADR (TEVA)

$19.61 +0.66 (3.48%)
Market Cap 21.73B
Revenue (ttm) 16.54B
Net Income (ttm) -1.64B
EPS (ttm) N/A
PE Ratio 7.61
Forward PE 7.69
Profit Margin -9.91%
Debt to Equity Ratio 2.52
Volume 8,650,380
Avg Vol 9,880,718
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 9%
Beta 0.71
Analysts Strong Sell
Price Target $24.88

Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 914 8213
Address:
124 Dvora HaNevi’a St., Tel Aviv, Israel
NNJAWINLIVE
NNJAWINLIVE Oct. 27 at 8:16 PM
$TEVA 30!!
0 · Reply
SHOWMETHEMONEY18
SHOWMETHEMONEY18 Oct. 27 at 6:16 PM
$TEVA 20.. !? Lets GO.
0 · Reply
Estimize
Estimize Oct. 27 at 2:12 PM
Wall St is expecting 0.68 EPS for $TEVA Q3 [Reporting 11/05 BMO] http://www.estimize.com/intro/teva?chart=historical&metric_name=eps&utm_co
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 27 at 1:39 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TEVA Current Share Price: $18.95 Contracts: $TEVA January 15, 2027 $20 Calls Scale in: $3.02- $3.69 Scale out: $4.69-$6.03 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com
0 · Reply
TR1000
TR1000 Oct. 26 at 3:59 PM
Here's one of the real reasons why stocks like $TEVA and many many others have been going nowhere. The other reason is we have RFK as the healthcare and biotech czar. Get him off that throne and the biotech sector will rally all the way back. Start from about 42 minutes in ... https://youtu.be/LvbK2kED3WI?si=VEk7y4DUV9NW2h_L
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 26 at 3:56 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TEVA Current Share Price: $18.95 Contracts: $TEVA January 15, 2027 $20 Calls Scale in: $3.02- $3.69 Scale out: $4.69-$6.03 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 11:00 PM
$TEVA That's what terror is like ....
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 10:54 PM
$TEVA No fun ...
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 10:53 PM
$TEVA Terror is ....
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 10:51 PM
$TEVA Terror is a ...
0 · Reply
Latest News on TEVA
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Oct 20, 2025, 4:30 PM EDT - 7 days ago

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

Oct 17, 2025, 12:18 PM EDT - 10 days ago

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

VTRS

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Oct 10, 2025, 3:00 PM EDT - 17 days ago

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside

Oct 7, 2025, 4:07 AM EDT - 20 days ago

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside

Teva Releases Q3 2025 Aide Memoire

Sep 25, 2025, 4:30 PM EDT - 4 weeks ago

Teva Releases Q3 2025 Aide Memoire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sep 25, 2025, 4:30 PM EDT - 4 weeks ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors

Sep 25, 2025, 11:42 AM EDT - 4 weeks ago

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 24, 2025, 7:23 AM EDT - 4 weeks ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited - Special Call

Sep 22, 2025, 2:53 PM EDT - 5 weeks ago

Teva Pharmaceutical Industries Limited - Special Call

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Sep 20, 2025, 10:15 PM EDT - 5 weeks ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Sep 17, 2025, 8:00 AM EDT - 5 weeks ago

Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Sep 16, 2025, 4:30 PM EDT - 5 weeks ago

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting

Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:57 PM EDT - 6 weeks ago

Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Colorado must face Teva's lawsuit over free allergy pen law

Sep 5, 2025, 3:57 PM EDT - 7 weeks ago

Colorado must face Teva's lawsuit over free allergy pen law

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Sep 2, 2025, 4:30 PM EDT - 7 weeks ago

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

US FDA approves Teva Pharmaceuticals' generic obesity drug

Aug 28, 2025, 9:17 AM EDT - 2 months ago

US FDA approves Teva Pharmaceuticals' generic obesity drug

Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue

Aug 28, 2025, 1:43 AM EDT - 2 months ago

Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

Aug 19, 2025, 9:00 AM EDT - 2 months ago

Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”

US FDA approves Teva's Ajovy for migraine prevention in children

Aug 5, 2025, 6:16 PM EDT - 2 months ago

US FDA approves Teva's Ajovy for migraine prevention in children

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

Jul 31, 2025, 3:27 PM EDT - 3 months ago

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

Teva CEO: Our supply chain puts us in a strong position

Jul 30, 2025, 12:40 PM EDT - 3 months ago

Teva CEO: Our supply chain puts us in a strong position

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 11:50 AM EDT - 3 months ago

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

Teva Pharm Q2 profit beats estimates as branded drugs gain

Jul 30, 2025, 7:21 AM EDT - 3 months ago

Teva Pharm Q2 profit beats estimates as branded drugs gain

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Jul 29, 2025, 2:44 PM EDT - 3 months ago

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Teva Releases Q2 2025 Aide Memoire

Jun 26, 2025, 4:30 PM EDT - 4 months ago

Teva Releases Q2 2025 Aide Memoire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Jun 25, 2025, 4:30 PM EDT - 4 months ago

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Jun 23, 2025, 3:00 AM EDT - 4 months ago

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Jun 16, 2025, 9:03 AM EDT - 4 months ago

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 10, 2025, 11:46 AM EDT - 4 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript

Jun 5, 2025, 7:09 AM EDT - 5 months ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Jun 3, 2025, 5:30 PM EDT - 5 months ago

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Jun 3, 2025, 7:16 AM EDT - 5 months ago

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

May 30, 2025, 9:05 PM EDT - 5 months ago

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

May 30, 2025, 9:00 PM EDT - 5 months ago

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

May 29, 2025, 8:00 AM EDT - 5 months ago

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

May 27, 2025, 5:30 PM EDT - 5 months ago

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

May 27, 2025, 4:30 PM EDT - 5 months ago

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Why Is Teva Stock Trading Higher On Tuesday?

May 27, 2025, 3:44 PM EDT - 5 months ago

Why Is Teva Stock Trading Higher On Tuesday?

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

May 27, 2025, 8:30 AM EDT - 5 months ago

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Why Investors Should Watch Teva Despite Regional Risks

May 23, 2025, 12:52 PM EDT - 5 months ago

Why Investors Should Watch Teva Despite Regional Risks

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

May 22, 2025, 1:56 PM EDT - 5 months ago

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

May 20, 2025, 5:22 PM EDT - 5 months ago

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

May 20, 2025, 4:30 PM EDT - 5 months ago

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

May 19, 2025, 4:52 AM EDT - 5 months ago

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

May 19, 2025, 4:52 AM EDT - 5 months ago

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

May 15, 2025, 6:12 PM EDT - 5 months ago

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside

May 8, 2025, 11:33 AM EDT - 6 months ago

Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says

May 7, 2025, 1:01 PM EDT - 6 months ago

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum

May 7, 2025, 12:13 PM EDT - 6 months ago

Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum

Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties

May 7, 2025, 11:51 AM EDT - 6 months ago

Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties

NNJAWINLIVE
NNJAWINLIVE Oct. 27 at 8:16 PM
$TEVA 30!!
0 · Reply
SHOWMETHEMONEY18
SHOWMETHEMONEY18 Oct. 27 at 6:16 PM
$TEVA 20.. !? Lets GO.
0 · Reply
Estimize
Estimize Oct. 27 at 2:12 PM
Wall St is expecting 0.68 EPS for $TEVA Q3 [Reporting 11/05 BMO] http://www.estimize.com/intro/teva?chart=historical&metric_name=eps&utm_co
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 27 at 1:39 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TEVA Current Share Price: $18.95 Contracts: $TEVA January 15, 2027 $20 Calls Scale in: $3.02- $3.69 Scale out: $4.69-$6.03 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com
0 · Reply
TR1000
TR1000 Oct. 26 at 3:59 PM
Here's one of the real reasons why stocks like $TEVA and many many others have been going nowhere. The other reason is we have RFK as the healthcare and biotech czar. Get him off that throne and the biotech sector will rally all the way back. Start from about 42 minutes in ... https://youtu.be/LvbK2kED3WI?si=VEk7y4DUV9NW2h_L
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 26 at 3:56 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TEVA Current Share Price: $18.95 Contracts: $TEVA January 15, 2027 $20 Calls Scale in: $3.02- $3.69 Scale out: $4.69-$6.03 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 11:00 PM
$TEVA That's what terror is like ....
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 10:54 PM
$TEVA No fun ...
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 10:53 PM
$TEVA Terror is ....
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 10:51 PM
$TEVA Terror is a ...
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 10:50 PM
$TEVA Nobody sucks for ...
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 10:46 PM
$TEVA Terror don't ....
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 10:44 PM
$TEVA The Terror is ....
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 6:48 PM
$TEVA To much Terror...
0 · Reply
Hopewisper
Hopewisper Oct. 24 at 6:47 PM
$TEVA Another piece of news... Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe https://share.google/eVC4jtPFwQ1Ue6jfk
0 · Reply
Terrordomo80
Terrordomo80 Oct. 24 at 2:29 PM
$TEVA And theres your garbage dumpster once again...underperforming and doing squat over a 5 day period while others are killing it in this never ending ponzi scheme of a market...you really have one special investment right here folks... Hope you'll be a little Wiser next time🤣🤣🤣
2 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 24 at 1:15 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TEVA Current Share Price: $19.02 Contracts: $TEVA January 15, 2027 $20 Calls Scale in: $3.25- $3.97 Scale out: $5.05-$6.49 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Terrordomo80
Terrordomo80 Oct. 23 at 3:30 PM
$TEVA Ah yes...another day in the life of TEVAdians... going to 25, 30 but cant hold 19... enjoy the ride...to nowhere....
0 · Reply
TR1000
TR1000 Oct. 23 at 3:05 AM
$TEVA is grotesquely underpriced
1 · Reply
Terrordomo80
Terrordomo80 Oct. 23 at 2:10 AM
$TEVA Dopewiser the dumbazz with more fantastic investment advice....
0 · Reply
Invest2live
Invest2live Oct. 22 at 7:50 PM
$MSFT 126% already; congrats 🎉 🌿🎈 Checkout $TTD and $TEVA
1 · Reply
BostonNorth
BostonNorth Oct. 22 at 6:45 PM
$TEVA $ SPRY This is long game for me!! $ SPRY — The Next EpiPen Standard First and only needle-free FDA + internationally approved treatment for type 1 allergic reactions (anaphylaxis). Launching by some of the same team that helped launch Narcan — patent protected to 2038. Highlights: • $250M non-dilutive funding • Approvals: 🇺🇸 USA, 🇬🇧 UK, 🇩🇪 Germany, 🇪🇺 Europe, 🇯🇵 Japan • Coming soon: 🇨🇦 Canada, 🇳🇿 New Zealand, Australia? • 30-month shelf life → lower cost, wider adoption • Insurance & school programs expanding fast • Currently in Phase 2 trials for treatment of hives (urticaria) My opinion only — do your own research. Good luck to all! The video below had over 7 million views but it was removed and reposted! https://youtu.be/INqeijbY9Q4
0 · Reply